CANTOS
Canakinumab Anti-inflammatory Thrombosis Outcomes Study
Patient / Population Intervention / Exposition Vergleich Endpunkt
In 10,061 patients with prior MI and elevated CRP, canakinumab reduced recurrent cardiovascular events compared with placebo.
N
10.061
Design
Double-blind RCT
Endpunkt
CV death, MI or stroke
Relevanz
2
ErgebnisHR 0.85, 95% CI 0.74–0.98, p=0.021 (150 mg); more fatal infections; no LDL change
Ridker PM, et al. N Engl J Med. 2017;377(12):1119-1131. 10.1056/NEJMoa1707914
Diskussion & Kritik
Proved the inflammatory hypothesis of atherosclerosis with a lipid-neutral drug. Cost and infection risk preclude routine use; pointed the way to colchicine.